Ultrasound for Lipohypertrophy in Diabetes Management
The Use of Ultrasound Detection of Lipohypertrophy to Improve Glycemic Control
Recruiting
N/A
Interventional Study
Diabetes Mellitus
Lipohypertrophy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 100 (estimated)
- Sponsor
- University of British Columbia · Other
Who this trial is looking for
This trial is looking for people with diabetes who use insulin. Participants will undergo ultrasound testing to check for a condition called lipohypertrophy, which may affect insulin absorption.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with Type 1 or Type 2 diabetes.
- I use insulin injections or an insulin pump at least once a day.
- I have been using insulin for at least 2 years.
You may not be able to join if
- I take a glucagon-like peptide-1 agonist.
- I take a systemic glucocorticoid.
- I have a history of a skin condition in the area where I inject insulin.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Lipohypertrophy is swelling of the fatty tissue located below the skin ("subcutaneous tissue") where many patients with diabetes inject their insulin. Lipohypertrophy can sometimes be felt as firm swelling, lumps or small bumps near insulin injection sites. Previous studies have shown that injecting insulin into areas of lipohypertrophy can affect how insulin is absorbed, and can increase insulin …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Subjects with a diagnosis of Type 1 or Type 2 diabetes mellitus
* Current treatment with a minimum of one insulin injection daily or insulin pump for at least 2 years
Exclusion Criteria:
* Subjects taking a glucagon-like peptide-1 agonist or a systemic glucocorticoid
* Past …
Contacts
No contact information available.